the company’s phase II clinical development stage » Globe Newswire - TCN.VN

Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform 20-06-2024, 21:46

Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers 23-04-2025, 14:30

LFG-to-RNG production to more than double by 2030, but project success depends on location and scale according to Wood Mackenzie 12-08-2024, 22:00

16-07-2024, 20:26

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis

Globe Newswire16-07-2024, 20:26

10-07-2024, 07:00

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal

Globe Newswire10-07-2024, 07:00

Liên hệ quảng cáo

Hotline hỗ trợ quảng cáo: 0914.222.131
Email: quangcao@vietsoftgroup.com

Email: info@vietsoftgroup.com

© Copyright 2019 - Trang tin tức chuyên đề giới trẻ TCN News - Toàn bộ bài viết được chi sẻ bởi các thành viên.